IEPFF for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
IEPFF may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 12,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed IEPFF in detail.
, Identification of Four Compounds with S-RBD-Binding and Pseudovirus Entry-Inhibitory Activity, International Journal of Molecular Sciences, doi:10.3390/ijms27188136
COVID-19, caused by SARS-CoV-2, remains a global health challenge because of viral evolution and immune escape. Although current therapies primarily target viral entry and replication, agents that directly interfere with the Spike receptor-binding domain (S-RBD) remain limited. Here, we combined virtual screening with biological validation to identify compounds capable of interfering with S-RBD function. A total of 3014 compounds from a customized drug library were screened by molecular docking. Candidate binding and functional activity were subsequently evaluated using cellular thermal shift assays, surface plasmon resonance, immunoprecipitation, immunofluorescence, and pseudovirus-entry assays against 2019-nCoV, Delta, and Omicron pseudoviruses. DOTAP chloride (KD = 49.94 μM), cefotiam hexetil hydrochloride (KD = 142.26 μM), melittin (KD = 34.98 μM), and teicoplanin (KD = 73.58 μM) showed detectable binding to the S-RBD and inhibited Spike-mediated pseudovirus entry. Molecular docking suggested that these interactions were mediated by potential binding modes involving hydrogen bonds and π-interactions. The compounds interfered with S-RBD/hACE2 colocalisation and inhibited pseudovirus entry with variant-dependent efficacy. DOTAP chloride (25 μM) inhibited entry of the 2019-nCoV and Omicron pseudoviruses, whereas the other three compounds showed activity across the tested variants. These findings identify four compounds with RBD-binding and entry-inhibition properties for further development as entry inhibitors.